To evaluate a smartphone-based AI platform for the early detection of ocular surface malignancies.
Approach:
Development of CaptureTumor (CaT): An AI-powered screening system combining smartphone photography, automated image analysis, public health outreach, and specialist referral pathways.
Training and Deployment: The deep-learning system was trained on over a decade of slit-lamp photographs and adapted for smartphone use, deployed as a WeChat Mini Program.
Public Engagement: The screening campaign reached over 256,000 people, with 13,243 accessing the application and 614 completing self-screening.
Performance Metrics: The system achieved an AUC of 0.977 in real-world screening, with sensitivity of 89.3% and specificity of 95.9%.
Key Findings:
The smartphone-based system identified 20 histopathologically confirmed malignancies, including 14 basal cell carcinomas and six malignant melanomas.
Nineteen cases were previously undiagnosed, indicating earlier detection.
Patients identified through the app required fewer referrals to access specialist services compared to historical averages.
Interpretation:
The study highlights the role of consumer technologies in enhancing ocular malignancy screening and improving access to care.
Limitations:
The study's findings are based on a specific population in China and may not be generalizable.
The self-screening process may have selection bias, as not all users may represent the broader population.
Conclusion:
The integration of AI-enabled self-screening with public health outreach may improve early detection of ocular malignancies.
Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.